Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation - EASY AF STUDY
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- OSU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female age ≥ 22 years and < 80 years
- Clinical decision to proceed with AF ablation procedure.
- Ablation procedure to be completed with General Anesthesia
- Ablation procedure to be completed with use of radiofrequency catheter ablation
Exclusion Criteria:
- History of various esophageal pathology such as esophageal achalasia, varices, strictures, web, carcinoma, tumor/mass, scleroderma, Mallory-Weiss tear, Barrett's esophagitis, diverticulum, banding, laceration, perforation, balloon dilatation.
- Presence of a pH probe deployed in the esophagus
- Planned AF ablation procedure to be completed with laser energy or with cryo-energy
- Acute or uncontrolled psychiatric illness
- Unable to undergo upper endoscopy
- Enrollment in another FDA clinical trial
- Unstable medical condition(s) that precludes safely completing study protocol
- Subject is incarcerated
- Subject is pregnant
- Subject is unable to comprehend the details of the study
- The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including the investigational device procedure and study-related follow up visit requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventional Group
Placement of a luminal esophageal temperature probe (LET) and insertion of esolution esophageal retractor.
In the intervention group, esolution will be utilized to deviate the esophagus during RF catheter ablation
|
esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
|
|
No Intervention: Control Group
Placement of a luminal esophageal temperature probe (LET) during RF ablation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of esophageal injury attributable to RF ablation energy as noted on post ablation endoscopy
Time Frame: 15-72 hours post-ablation procedure
|
The primary study endpoint is the incidence of esophageal injury attributable to RF ablation energy as noted on post ablation endoscopy
|
15-72 hours post-ablation procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EASY AF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.